Cat. No. | Product Name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T10635 | Burixafor hydrobromide
化合物 T10635
|
1191450-19-7 | 98% |
|
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in tre... | ||||
T78879 | CXCR4-IN-2
化合物 CXCR4-IN-2
|
98% |
|
|
CXCR4-IN-2(compound A1)是一款具有抗癌活性的双功能氟化小分子,是CXCR4的强效抑制剂。它对小鼠结直肠癌(CRC)细胞展现出显著的细胞毒性(IC50:60 μg/mL;72小时)和抗增殖能力,能够引导细胞在G2/M期发生阻滞并诱导细胞凋亡(apoptosis)。 | ||||
T79059 | CXCR4-IN-1
化合物 CXCR4-IN-1
|
2304750-48-7 | 98% |
|
CXCR4-IN-1 (Example C5) 为CXCR4抑制剂,IC50值为20 nM。该化合物主要适用于癌症、HIV、糖尿病视网膜病变、炎症等领域的研究。 | ||||
T79070 | Pentixafor
化合物 Pentixafor
|
1341207-62-2 | 98% |
|
Pentixafor是靶向CXCR4受体的肽类化合物,可结合68Gallium (68Ga) 进行正电子发射断层扫描 (PET) 成像。 | ||||
T80130 | SDF-1α (human)
化合物 SDF-1α (human)
|
1268129-65-2 | 98% |
|
SDF-1α (human) 是一种能够与CXCR4受体相结合的单核细胞趋化剂,它在心肌梗死模型中的干细胞归巢、维持、生存、增殖、心肌细胞修复、血管形成以及心室重构过程扮演关键角色。SDF-1α (human) 常用于心血管病研究。 | ||||
T80216 | DOTA-CXCR4-L
化合物 DOTA-CXCR4-L
|
98% |
|
|
DOTA-CXCR4-L为针对CXCR4的靶向肽,适用于癌症研究,如胶质母细胞瘤和三阴性乳腺癌。 | ||||
T80525 | E70K
化合物 E70K
|
98% |
|
|
E70K是CXCL8 C端肽的变体,其第70位的谷氨酸被赖氨酸取代。该化合物能够降低炎症过程中中性粒细胞的粘附与迁移。 | ||||
T11140 | E6130
化合物 T11140
|
1427058-33-0 | 98% |
|
E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration. | ||||
T16933 | SRT3190
化合物 T16933
|
1204707-73-2 | 98% |
|
SRT3190 is an antagonist of CXCR2. | ||||
T12269L | NUCC-390 dihydrochloride (1060524-97-1 free base)
化合物 T12269L
|
T12269L | 98% |
|
NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor. | ||||
TN5227 | (+/-)-Vestitol
化合物 TN5227
|
56701-24-7 | 98% |
|
Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to... | ||||
T16864 | SCH 563705
化合物 T16864
|
473728-58-4 | 98% |
|
SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively). | ||||
T19386 | ITIC
化合物 T19386
|
1664293-06-4 | 98% |
|
ITIC, a non-fullerene acceptor, demonstrates exceptional thermal stability and exhibits a glass-crystal transition at a significantly lower temperature than its ... | ||||
T6764 | ATI-2341
化合物ATI-2341
|
1337878-62-2 | 98% |
|
ATI-2341 是 C-X-C 趋化因子受体 4 型功能选择性变构激动剂,作为偏向配体有利于 Gα1 激活。它是一种变构激动剂,可激活抑制性异源三聚体 G 蛋白 (Gi) 以促进抑制 cAMP 产生并诱导钙动员。 | ||||
T19385 | ITIC-4F
化合物 T19385
|
2097998-59-7 | 98% |
|
ITIC-4F, an indacenodithienothiophene (IDTT)-based postfullerene electron acceptor, exhibits wide applicability in high-efficiency binary and ternary single-junc... | ||||
TP2141 | Balixafortide TFA (1051366-32-5 free base)
化合物 TP2141
|
TP2141 | 98% |
|
Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large pane... | ||||
T14665 | Motixafortide
化合物 T14665
|
664334-36-5 | 98% |
|
Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM). | ||||
TP2141L | Balixafortide
化合物 TP2141L
|
1051366-32-5 | 98% |
|
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and prog... | ||||
T0801 | Tannic acid
单宁酸
|
1401-55-4 | AR |
|
Tannic acid (Gallotannic acid) 是新型hERG 通道阻塞剂,IC50为 3.4 μM。 | ||||
T1739 | WZ811
化合物WZ811
|
55778-02-4 | 99.93% |
|
WZ811 是可口服的高竞争性CXCR4拮抗剂,抑制细胞中 CXCR4/SDF-1 介导的 cAMP 水平调节和 SDF-1 诱导的基质胶侵入,EC50为 1.2 和 5.2 nM。 |